Open AccessIdentification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis
Author(s) -
Roselie Achten,
Chantal van Luijk,
Lisa Van der Rijst,
Daphne Bakker,
Lotte S Spekhorst,
Nicolaas P. A. Zuithoff,
Marie L A Schuttelaar,
Geertruida L E Romeijn,
Angelique N. Voorberg,
Marijke Kamsteeg,
Inge Haeck,
Marlies de Graaf,
Judith L. Thijs,
Joke de Boer,
Marjolein de BruinWeller
Publication year - 2022
Publication title -
acta dermato-venereologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.982
H-Index - 83
eISSN - 1651-2057
pISSN - 0001-5555
DOI - 10.2340/actadv.v102.1128
Subject(s) - dupilumab , atopic dermatitis , medicine , odds ratio , dermatology , logistic regression , disease , multivariate analysis
This study identified risk factors for the development of dupilumab-associated ocular surface disease in patients with moderate-to-severe atopic dermatitis in a large prospective daily practice cohort. Data from the Dutch BioDay Registry were used to assess the risk of developing dupilumab-associated ocular surface disease, by performing univariate and multivariate logistic regression analyses. A total of 469 patients were included, of which 152/469 (32.4%) developed dupilumab-associated ocular surface disease. Multivariate analysis showed a statistically significant association of the development of dupilumab-associated ocular surface disease with a history of any eye disease (history of self-reported episodic acute allergic conjunctivitis excluded) combined with the use of ophthalmic medication at the start of dupilumab (odds ratio 5.16, 95% confidence interval 2.30–11.56, p < 0.001). In conclusion, a history of any eye disease (history of self-reported episodic acute allergic conjunctivitis excluded) combined with the use of ophthalmic medication at baseline was associated with the development of dupilumab-associated ocular surface disease in patients with atopic dermatitis.